TNFSF13B and myasthenia gravis: B cell targeting drugs can exert an indirect effect, by promoting inhibition of B cells via blockage of their stimulating factors, such as BAFF that is able to induce B-cell survival and differentiation, the levels of which are increased in MG patients’ sera (44).